Peral Bolaños Cristina, Santaolalla García Isabel, Gómez Valbuena Isabel, Vega Ruíz Laura, Iglesias Carabias Claudia, Martín Valero Rocío, Martínez Martínez Fernando
Gerencia Asistencial de Atención Primaria de la Comunidad de Madrid, Dirección Asistencial Sureste, Madrid, España.
Gerencia Asistencial de Atención Primaria de la Comunidad de Madrid, Dirección Asistencial Sureste, Madrid, España.
Aten Primaria. 2024 Oct;56(10):102959. doi: 10.1016/j.aprim.2024.102959. Epub 2024 May 18.
To describe the Drug-Related Problems (DRP) and their resolution after pharmacological review in institutionalised elderly patients under polypharmacy.
Descriptive, retrospective cohort study from January to October of 2022.
Twelve nursing homes at the Community of Madrid.
295 patients aged 65 or older taking at least 5 chronic medications prescribed prior to the treatment review.
Medication reviews carried out by the pharmacist and agreed upon in face-to-face meetings between the primary care doctor, the nursing home doctor and the pharmacist.
Detected DRP, types and resolution. A age, sex, and number of medications before and after the intervention. Pharmacological subgroups according to anatomical therapeutic chemical classification system (ATC) and active pharmaceutical ingredients involved in the detected DRPs.
1425 DRP were detected, with a mean of 4.85 (SD 3.33) DRPs/patient. The most frequent DRP was reconciliation error (32.52%), followed by pharmaceutical regimen and dosaje. Among the 1425 improvement proposals, 86.73% of them were accepted.Significant statistically differences were observed between the number of medications per patient prior to the pharmacotherapy review (12.29) and after it (10.20), obtaining an average difference of 2.09 (95%CI: 1.98-2.21; P<.001).
It is found that the intervention of multidisciplinary team in which the pharmacist performs a revision of the medication decreased the number of prescribed medications. Therefore, it reduces polymedication and its associated risks.
描述多重用药的机构化老年患者药物相关问题（DRP）及其在药物审查后的解决情况。
2022年1月至10月的描述性回顾性队列研究。
马德里自治区的12家养老院。
295名65岁及以上的患者，在治疗审查前服用至少5种慢性药物。
由药剂师进行药物审查，并在初级保健医生、养老院医生和药剂师之间的面对面会议上达成一致。
检测到的DRP、类型和解决情况。干预前后的年龄、性别和药物数量。根据解剖治疗化学分类系统（ATC）和检测到的DRP中涉及的活性药物成分划分的药理学亚组。
共检测到1425个DRP，平均每位患者4.85个（标准差3.33）。最常见的DRP是核对错误（32.52%），其次是药物治疗方案和剂量。在1425条改进建议中，86.73%被接受。在药物治疗审查前每位患者的药物数量（12.29）和审查后（10.20）之间观察到显著的统计学差异，平均差异为2.09（95%置信区间：1.98 - 2.21；P <.001）。
发现药剂师参与的多学科团队干预减少了处方药物的数量。因此，它减少了多重用药及其相关风险。
